Local melatonin regulates inflammation resolution: A common factor in neurodegenerative, psychiatric and systemic inflammatory disorders

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 5, 2014, Pages 817-827

  Anderson, George ^a   Maes, Michael ^b,c  

^a CRC   (United Kingdom)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Glioblastoma; Inflammation; Melatonin; Neurodegeneration; Neuroinflammation; Oxidative and nitrosative stress; Psychiatric

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; HIGH MOBILITY GROUP B2 PROTEIN; INDOLEAMINE 2, 3 DIOXYGENASE; MELATONIN; MELATONIN 1 RECEPTOR; METHYL CPG BINDING PROTEIN 2; MOOD STABILIZER; N ACETYLSEROTONIN; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR YY1; TRYPTOPHAN; UNCLASSIFIED DRUG; VALPROIC ACID; N-ACETYLSEROTONIN;

ALZHEIMER DISEASE; AUTISM; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; GENETIC ASSOCIATION; GLIOBLASTOMA; HORMONE SYNTHESIS; HUMAN; MENTAL DISEASE; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; COMPLICATION; INFLAMMATION; MENTAL DISORDERS; METABOLISM;

HUMANS; INFLAMMATION; MELATONIN; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; SEROTONIN;

EID: 84905579390     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140711091400     Document Type: Review

References (91)

1. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011; 76: 54-60.
2. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol Lett 2011; 32(1): 7-24.
3. Derecki NC, Cronk JC, Lu Z, et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012; 484(7392): 105-9.
4. Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010; 468(7321): 263-9.
5. Nelson ED, Kavalali ET, Monteggia LM. MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. Curr Biol 2006; 16(7): 710-6.
6. Lioy DT, Garg SK, Monaghan CE, et al. A role for glia in the progression of Rett's syndrome. Nature 2011; 475(7357): 497-500.
7. Derecki NC, Cronk JC, Kipnis J. The role of microglia in brain maintenance: implications for Rett syndrome. Trends Immunol 2013; 34(3): 144-50.
8. Joyner AH, Roddey JC, Bloss CS, et al. A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proc Natl Acad Sci USA 2009; 106(36): 15483-8.
9. Gantz SC, Ford CP, Neve KA, Williams JT. Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway. J Neurosci 2011; 31(35): 12629-37.
10. Piton A, Gauthier J, Hamdan FF, et al. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiat 2011; 16(8): 867-80.
11. Neul JL. The relationship of Rett syndrome and MECP2 disorders to autism. Dialogues Clin Neurosci 2012; 14: 253-62.
12. Hutchinson AN, Deng JV, Cohen S, West AE. Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action. J Neurosci 2012; 32(41): 14355-63.
13. Hutchinson AN, Deng JV, Aryal DK, Wetsel WC, West AE. Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. Neuropsychopharmacology 2012; 37: 321-37.
14. Anderson G, Maes M. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol Dis Drug Targets 2014; 13(1): 137-49.
15. Anderson G, Rodriguez M. Multiple Sclerosis, seizures and antiepileptics: role of IL-18: IDO and melatonin. Eur J Neurol 2011; 18(5): 680-5.
16. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Br Dis 2012; 27(2): 113-9.
17. Srinivasan V, Cardinali DP, Srinivasan US, et al. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 2011; 4(5): 297-317.
18. Anderson G, Maes M. Oxidative/Nitrosative Stress and immunoinflammatory pathways in depression: treatment implications. Curr Pharm Design 2014; in press.
19. Maes M, Kubera M, Leunis JC, et al. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS): and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 2013; 127(5): 344-54.
20. Essa MM, Braidy N, Waly MI, et al. Impaired antioxidant status and reduced energy metabolism in autistic children. Res Aut Spect Dis 2013; 7: 557-65.
21. Dodd S, Maes M, Anderson G, et al. Putative neuroprotective agents in major psychoses. Prog Neuropsychopharmacol Biol Psychiat 2013; 42: 135-45.
22. Anderson G, Maes M. Metabolic Syndrome, Alzheimer's, Schizophrenia and Depression: Role for Leptin, Melatonin, Kynurenine Pathways and Neuropeptides. In: Metabolic Syndrome and Neurological Disorders; Farooqui T, Farooqui AA, Eds.; John Wiley & Sons Ltd, Chichester, UK 2013; Chapter 13.
23. Srinivasan V, Shillcott SD, Oter S, Brzezinski A, Eds.; Melatonin and Melatonergic drugs in clinical practice. Springer 2014.
24. Ono K, Mochizuki H, Ikeda T, et al. Effect of melatonin on α-synuclein self-assembly and cytotoxicity. Neurobiol Aging 2012; 33(9): 2172-85.
25. Martín M, Macías M, León J, et al. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34(4): 348-57.
26. da Silveira Cruz-Machado S, Pinato L, Tamura EK, Carvalho-Sousa CE, Markus RP. Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS One 2012; 7(7): e40142.
27. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res 2007; 43: 365-71.
28. Hriscu M, Saulea G, Ostriceanu S, Baciu I. Circadian phagocytic activity in rats under light-dark and constant light regimens. Rom J Physiol 2002-2003; 39-40: 17-26.
29. Lardone PJ, Carrillo-Vico A, Naranjo MC, et al. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physiol 2006; 206: 273-9.
30. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012; 10: 66.
31. Muxel SM, Pires-Lapa MA, Monteiro AWA, et al. NF-kB Drives the Synthesis of Melatonin in RAW 264. 7 Macrophages by Inducing the Transcription of the Arylalkylamine-NAcetyltransferase (AA-NAT) Gene. PLoS ONE 2012; 7(12): e52010.
32. Liu YJ, Zhuang J, Zhu HY, et al. Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J Pineal Res 2007; 43(3): 232-8.
33. Tan DX, Manchester LC, Liu X, et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res 2013; 54: 127-38.
34. Sharma R, Ottenhof T, Rzeczkowska PA, Niles LP. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17. 2 neural stem cells. J Pineal Res 2008; 45(3): 277-84.
35. Bernard M, Voisin P. Photoreceptor-specific expression, lightdependent localization, and transcriptional targets of the zinc-finger protein Yin Yang 1 in the chicken retina. J Neurochem 2008; 105(3): 595-604.
36. Nowak K, Lange-Dohna C, Zeitschel U, et al. The transcription factor Yin Yang 1 is an activator of BACE1 expression. J. Neurochem 2006; 96(6): 1696-707.
37. Forlani G, Giarda E, Ala U, et al. The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis. Hum Mol Genet 2010; 19(16): 3114-23.
38. Bauer MKA, Schubert A, Rocks O, Grimm S. Adenine nucleotide translocase-1: a component of the permeability pore, can dominantly induce apoptosis. J Cell Biol 2006; 147: 1493-501.
39. Rylski M, Amborska R, Zybura K, et al. Yin Yang 1 expression in the adult rodent brain. Neurochem Res 2008; 33(12): 2556-64.
40. Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO. Proinflammatory interleukin-18 increases Alzheimer's disease associated amyloid-B production in human neuron-like cells. J Neuroinflamm 2012; 9: 199.
41. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 69-91.
42. Anderson G, Ojala JO. Alzheimer's and Seizures: Interleukin-18: Indoleamine 2: 3-Dioxygenase and Quinolinic Acid. Int J Trytophan Res 2010; 3: 169-73.
43. Liu YJ, Meng FT, Wang LL, et al. Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells. J Pineal Res 2012; 52(4): 397-402.
44. Michels A, Multhammer M, Zintl M, Mendoza MC, Klünemann HH. Association of apolipoprotein E ε4 (ApoE ε4) homozygosity with psychiatric behavioral symptoms. J Alzheimers Dis 2012; 28(1): 25-32.
45. Comijs HC, van den Kommer TN, Minnaar RW, Penninx BW, Deeg DJ. Accumulated and differential effects of life events on cognitive decline in older persons: depending on depression, baseline cognition, or ApoE epsilon4 status? J Gerontol B Psychol Sci Soc Sci 2011; 66(Suppl 1): i111-20.
46. Wegiel J, Frackowiak J, Mazur-Kolecka B, et al. Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11. 2-q13 autism spectrum disorders. PLoS One 2012; 7(5): e35414.
47. De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999; 53(8): 1628-33.
48. Villapol S, Fau S, Renolleau S, et al. Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr Res 2011; 69(1): 51-5.
49. Natarajan R, Einarsdottir E, Riutta A, et al. Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. J Neuroimmunol 2012; 250(1-2): 106-10.
50. Tamam Y, Tasdemir N, Yalman M, Tamam B. Association of apolipoprotein E genotypes with prognosis in multiple sclerosis. Eur Rev Med Pharmacol Sci 2011; 15(10): 1122-30.
51. Gabellini D, Green MR, Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2002; 110: 339-48.
52. Huang W, Tang Y, Li L. HMGB1: a potent proinflammatory cytokine in sepsis. Cytokine 2010; 51: 119-126.
53. Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res 2011; 50(4): 403-11.
54. Lee SE, Kim SJ, Youn JP, et al. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res 2011; 51: 345-52.
55. Kefas B, Godlewski J, Comeau L. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is downregulated in glioblastoma. Can Res 2008; 68: 3566-72.
56. Zhang N, Li X, Wu CW, et al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene 2013; 32(42): 5078-88.
57. Didier N, Romero IA, Créminon C, et al. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003; 86(1): 246-54.
58. Argaw AT, Asp L, Zhang J, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012; 122(7): 2454-568.
59. Liu Y, Hu J, Wu J, et al. α7 nicotinic acetylcholine receptormediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation. J Neuroinflamm 2012; 9: 98.
60. Mishra NC, Rirsimaah J, Boyd RT, et al. Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors. J Immunol 2010; 185(1): 588-96.
61. Markus RP, Silva CL, Franco DG, Barbosa EM Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Ther 2010; 126(3): 251-62.
62. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008; 105(4): 1333-8.
63. Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr 1996; 8(4): 348-354.
64. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010; 626(1): 64-71.
65. Soliman A, Udemgba C, Fan I, et al. Convergent effects of acute stress and glucocorticoid exposure upon MAO-A in humans. J Neurosci 2012; 32(48): 17120-7.
66. Yanez M, Vina D. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. Curr Top Med Chem 2013; 13(14): 1692-706.
67. Gulyás B, Pavlova E, Kása P, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int 2011; 58(1): 60-8.
68. Carter SF, Schöl lM, Almkvist O, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-Ldeprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 2012; 53(1): 37-46.
69. Luchowska E, Kloc R, Olajossy B, et al. Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiat 2009; 33: 519-29.
70. Funakoshi H, Kanai M, Nakamura T. Modulation of tryptophan metabolism, promotion of neurogenesis and alteration of anxietyrelated behavior in tryptophan 2: 3-dioxygenase-deficient mice. Int J Tryptoph Res 2011; 4: 7-18.
71. Anderson G, Maes M. Schizophrenia: Linking prenatal infection to hypoNMDAr, Immune-inflammation, demyelination, susceptibility genes, IDO, neuroprogression and treatment. Prog NeuroPharm Biol Psychiatr 2013; 42: 5-19.
72. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics 2011; 128: 344-55.
73. Krstic D, Madhusudan A, Doehner J, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflamm 2012; 9(1): 151.
74. Ilbäck NG, Lindh U, Minqin R, Friman G, Watt F. Selenium and mercury are redistributed to the brain during viral infection in mice. Biol Trace Elem Res 2005; 108: 215-24.
75. Bihaqi SW, Huang H, Wu J, Zawia NH. Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: implications for Alzheimer's disease. J Alzheimers Dis 2011: 27(4): 819-33.
76. Bihaqi SW, Zawia NH. Alzheimer's disease biomarkers and epigenetic intermediates following exposure to Pb in vitro. Curr Alzheimer Res 2012; 9(5): 555-62.
77. Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 2007; 4(2): 219-28.
78. Yawno T, Castillo-Melendez M, Jenkin G, et al. Mechanisms of melatonin-induced protection in the brain of late gestation fetal sheep in response to hypoxia. Dev Neurosci 2012; 34(6): 543-51.
79. Anderson G, Maes M. Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala. Curr Neuropharmacol 2014; 12(2): 148-67.
80. Anderson G, Beischlag TV, Vinciguerra M, Mazzoccoli G. The circadian clock circuitry and the AHR signaling pathway in physiology and pathology. Biochem Pharmacol 2013; 85: 1405-16.
81. Wang J, Hao H, Yao L, et al. Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J Pineal Res 2012; 53(2): 180-7.
82. Jablonska K, Pula B, Zemla A, et al. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J Pineal Res 2013; 54(3): 334-45.
83. Shao Z, Dyck LE, Wang H, Li XM. Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells. J Psychiat Neurosci 2006; 31(1): 32-7.
84. Castro LM, Gallant M, Niles LP. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005; 95(5): 1227-36.
85. Mercier G, Lennon AM, Renouf B, et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004; 24(2): 207-16.
86. Allaman I, Fiumelli H, Magistretti PJ, Martin JL. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 2011; 216(1): 75-84.
87. Anderson G, Maes M. Reconceptualizing adult neurogenesis: role for s1p and fgf1 in co-ordinating astrocyte-neuronal precursor interactions. CNS Neurol Disord Drug Targets 2014; 13(1): 126-36.
88. Kim B, Rincón Castro LM, Jawed S, Niles LP. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur J Pharmacol 2008; 589(1-3): 45-8.
89. Jawed S, Kim B, Ottenhof T, et al. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 2007; 560(1): 17-22.
90. Wadhwa S, Nag TC, Jindal A, et al. Expression of the neurotrophin receptors Trk A and TrkB in adult human astrocytoma and glioblastoma. J Biosci 2003; 28(2): 181-8.
91. Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012; 21(18): 4030-7.